[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Houchaymi Z, Helou S, Ballout J: [Pericardial tamponade and third-degree atrioventricular block revealing a primary cardiac lymphoma]. Rev Med Interne; 2010 Nov;31(11):e4-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pericardial tamponade and third-degree atrioventricular block revealing a primary cardiac lymphoma].
  • Secondary and primary cardiac tumors are rare, and primary cardiac lymphoma are exceptional.
  • Analysis of the pericardial fluid and tissue was not contributive.
  • À transvenous biopsy of the cardiac tumour revealed non-Hodgkin large B-cell lymphoma (CD45+ CD20+ CD3-BCl2+).
  • Therapy is based on chemotherapy.
  • However, prognosis remains poor for this type of tumor commonly revealed by a pericardial effusion.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20605278.001).
  • [ISSN] 1768-3122
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


2. Avilés A, Neri N, Nambo JM, Huerta-Guzman J, Talavera A, Cleto S: Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma; 2005 Jul;46(7):1023-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.
  • Anthracyclines are a group of drugs that are useful in the treatment of Hodgkin's disease, but have been associated with severe, and in some cases lethal, cardiac toxicity.
  • Apparently, cardiac toxicity is more frequent after 10 years of anthracycline therapy, but no longer studies of cardiac toxicity have been reported.
  • The endpoint was the presence of a clinical cardiac event (CCE) or abnormalities in equilibrium radionuclide angiocardiography (ERNA) and echocardiogram.
  • The patients did not receive radiation therapy and when relapsed they were censored from cardiac toxicity.
  • Overall survival was better in patients treated with EBVD because less cardiac events were observed.
  • The use of mitoxantrone was associated with a high rate of relapse and cardiac events.
  • Thus, we would not recommend use of the drug in Hodgkin's disease.
  • ERNA and echocardiogram are early detection tests for cardiac toxicity and can be employed in surveillance studies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Heart / drug effects. Heart Diseases / chemically induced. Hodgkin Disease / drug therapy. Mitoxantrone / adverse effects
  • [MeSH-minor] Adolescent. Adult. Bleomycin / adverse effects. Dacarbazine / adverse effects. Disease-Free Survival. Doxorubicin / adverse effects. Echocardiography. Epirubicin / adverse effects. Female. Gated Blood-Pool Imaging. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Survival Rate. Treatment Outcome. Vinblastine / adverse effects

  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019553.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; BZ114NVM5P / Mitoxantrone; ABVD protocol; EBVD protocol
  •  go-up   go-down


3. Timperley J, Mitchell AR, Becher H: Primary cardiac lymphoma. Eur J Echocardiogr; 2003 Dec;4(4):327-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac lymphoma.
  • We present a case of primary cardiac lymphoma, which is a rare condition compared with secondary metastatic involvement and is associated with poor prognosis.
  • This case demonstrates the use of transthoracic echocardiography for the assessment of tumour regression in response to chemotherapy.
  • [MeSH-major] Heart Neoplasms / ultrasonography. Lymphoma, B-Cell / ultrasonography
  • [MeSH-minor] Aged. Echocardiography. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14611830.001).
  • [ISSN] 1525-2167
  • [Journal-full-title] European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
  • [ISO-abbreviation] Eur J Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Porea TJ, Dreyer ZE, Bricker JT, Mahoney DH Jr: Evaluation of left ventricular function in asymptomatic children about to undergo anthracycline-based chemotherapy for acute leukemia: an outcome study. J Pediatr Hematol Oncol; 2001 Oct;23(7):420-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of left ventricular function in asymptomatic children about to undergo anthracycline-based chemotherapy for acute leukemia: an outcome study.
  • BACKGROUND: Cardiac toxicity is a well-recognized potential complication of anthracycline use.
  • Children treated with anthracyclines undergo several cardiac screening procedures before therapy, but the usefulness of these pretherapy cardiac studies has never been evaluated.
  • The authors examined whether induction chemotherapy in patients with high-risk acute lymphoblastic leukemia (ALL) was altered based on a pretherapy left ventricular shortening fraction (SF).
  • PATIENTS AND METHODS: Medical records of 134 children registered on treatment protocols of the Pediatric Oncology Group for high-risk B-precursor and T-cell ALL between 1987 and 1998 were reviewed.
  • Demographic information consisting of age at diagnosis, sex, and past cardiac history was collected, as were the results of all echocardiographic evaluations for SF and actions taken based on these evaluations.
  • The outcome measured was whether any changes were made in induction therapy based on initial SF.
  • In addition, secondary SF results obtained at the cumulative anthracycline dose range of 90 to 150 mg/m2 were studied to determine whether modifications of future chemotherapy were made after this limited exposure.
  • RESULTS: Three of 128 children (2.3%) without a previous cardiac history had an initial SF on their pretherapy echocardiogram that prompted additional evaluation but no change in therapy.
  • A secondary analysis of SF in 85 children who completed anthracycline doses of 90 to 150 mg/m2 was performed.
  • No cardiac dysfunction occurred among these six patients during later follow-up.
  • CONCLUSIONS: In the absence of a previous cardiac history or signs and symptoms or cardiac disease, pretherapy evaluation of left ventricular function may not be indicated in children about to undergo anthracycline-based treatment of acute leukemia.
  • The timing of initiation of cardiac evaluation remains unclear, but these results suggest that even at a cumulative dose of 90 to 150 mg/m2, studies to determine left ventricular function do not yield data sufficient to warrant a change in the clinical management of these patients.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Heart / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Ventricular Function, Left / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11878575.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  •  go-up   go-down


5. Langebrake C, Reinhardt D, Ritter J: Minimising the long-term adverse effects of childhood leukaemia therapy. Drug Saf; 2002;25(15):1057-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimising the long-term adverse effects of childhood leukaemia therapy.
  • The treatment of acute leukaemias consists of sequential therapy cycles (induction, consolidation, intensification, maintenance therapy) with different cytostatic drugs over a time period of up to 1.5-3 years.
  • Therefore, growing attention is now focused on the long-term effects of antileukaemic treatment.
  • Several cytostatic drugs administered in the treatment of acute leukaemia in childhood are known to cause long-term adverse effects.
  • Anthracyclines may induce chronic cardiotoxicity, alkylating agents are likely to cause gonadal damage and secondary malignancies and the use of glucocorticoids may cause osteonecrosis.
  • Approaches to minimising long-term adverse effects without jeopardising outcome have included: the design of new drugs such as a liposomal formulation of anthracyclines, the development of anthracycline-derivates with lower toxicity, the development of cardioprotective agents or, more recently, the use of targeted therapy;alternative administration schedules like continuous infusion or timed sequential therapy; and risk group stratification by the monitoring of minimal residual disease.
  • Several attempts have been made to minimise the cardiotoxicity of anthracyclines: decreasing concentrations delivered to the myocardium by either prolonging infusion time or using liposomal formulated anthracyclines or less cardiotoxic analogues, or the additional administration of cardioprotective agents.
  • The use of new diagnostic methods, such as diagnosis of minimal residual disease, which allow reduction or optimisation of dose, offer potential advantages compared with conventional treatment in terms of reducing the risk of severe long-term adverse effects.
  • Most options for minimising long-term adverse effects have resulted from theoretical models and in vitro studies, but only some of the modalities such as the use of dexrazoxane, the continuous infusion of anthracyclines or timed sequential therapy, have been evaluated in prospective, randomised studies in patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia / drug therapy
  • [MeSH-minor] Alkylating Agents / adverse effects. Alkylating Agents / therapeutic use. Anthracyclines / adverse effects. Anthracyclines / therapeutic use. Antimetabolites / adverse effects. Antimetabolites / therapeutic use. Asparaginase / adverse effects. Asparaginase / therapeutic use. Asparagine / adverse effects. Asparagine / therapeutic use. Cardiovascular Diseases / chemically induced. Child. Clinical Trials as Topic. Glucocorticoids / adverse effects. Glucocorticoids / therapeutic use. Gonadal Disorders / chemically induced. Humans. Leukemia, Myeloid, Acute / drug therapy. Osteonecrosis / chemically induced. Podophyllotoxin / adverse effects. Podophyllotoxin / therapeutic use. Polyethylene Glycols / adverse effects. Polyethylene Glycols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Tretinoin / adverse effects. Tretinoin / therapeutic use. Vinca Alkaloids / adverse effects. Vinca Alkaloids / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. PODOFILOX .
  • Hazardous Substances Data Bank. ASPARAGINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Oncol. 2001 Nov;13(6):522-7 [11673694.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):7-14 [11443603.001]
  • [Cites] Hematol Cell Ther. 1996 Apr;38(2):169-76 [8931998.001]
  • [Cites] Med Pediatr Oncol. 2001 Oct;37(4):365-71 [11568900.001]
  • [Cites] Leukemia. 2000 Sep;14(9):1570-6 [10995002.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):713-26 [11380463.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):130-40 [9576193.001]
  • [Cites] Oncology. 1995 May-Jun;52(3):251-5 [7715910.001]
  • [Cites] Cancer. 1983 Dec 1;52(11):2162-4 [6578869.001]
  • [Cites] Ann Intern Med. 1979 Nov;91(5):710-7 [496103.001]
  • [Cites] Cancer Res. 1986 Jul;46(7):3722-7 [3458531.001]
  • [Cites] Ann Pharmacother. 1994 Sep;28(9):1063-72 [7803884.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):196-200 [7904666.001]
  • [Cites] Cancer. 1991 Aug 1;68(3):600-4 [1648435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):379-84 [9788419.001]
  • [Cites] Drugs Aging. 1996 Aug;9(2):122-47 [8820798.001]
  • [Cites] J Drug Target. 1996;4(3):129-40 [8959485.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2705-13 [11352963.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1176-81 [7850718.001]
  • [Cites] J Natl Cancer Inst. 1988 Jun 15;80(8):556-66 [3286879.001]
  • [Cites] Blood. 2002 Jan 1;99(1):245-51 [11756178.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3262-72 [10986059.001]
  • [Cites] Br J Haematol. 1998 Aug;102(3):729-39 [9722300.001]
  • [Cites] Cancer Treat Rep. 1986 Oct;70(10 ):1187-93 [3530445.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1490-6 [11410481.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1444-54 [11230490.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3016-20 [9738570.001]
  • [Cites] Blood. 1998 Jul 15;92(2):411-5 [9657739.001]
  • [Cites] Cytokines Mol Ther. 1996 Jun;2(2):121-33 [9384697.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1046-54 [8501490.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5 Suppl 17):9-18 [11740802.001]
  • [Cites] Med Pediatr Oncol. 1993;21(7):477-9 [8341214.001]
  • [Cites] Med Klin (Munich). 2002 Jan 15;97 Suppl 1:16-21 [11831066.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3):347-61 [10864222.001]
  • [Cites] Curr Opin Investig Drugs. 2002 Mar;3(3):492-9 [12054102.001]
  • [Cites] Leukemia. 2001 Jun;15(6):898-902 [11417474.001]
  • [Cites] Drugs. 1997;54 Suppl 4:1-7 [9361955.001]
  • [Cites] Cancer Res. 1982 May;42(5):1817-25 [7066898.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1939-45 [8083715.001]
  • [Cites] Invest New Drugs. 1997;15(3):247-53 [9387047.001]
  • [Cites] Am J Clin Oncol. 1994 Dec;17(6):498-501 [7977168.001]
  • [Cites] Prog Cardiovasc Dis. 1986 May-Jun;28(6):449-62 [3010377.001]
  • [Cites] Br J Haematol. 2002 Feb;116(2):308-15 [11841431.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4979-89 [8652810.001]
  • [Cites] Cancer. 1990 Feb 15;65(4):870-3 [2297656.001]
  • [Cites] Leukemia. 2001 Mar;15(3):348-54 [11237056.001]
  • [Cites] Arch Int Pharmacodyn Ther. 1992 Sep-Oct;319:58-65 [1285674.001]
  • [Cites] Ital Heart J Suppl. 2000 Nov;1(11):1457-63 [11109196.001]
  • [Cites] Drug Resist Updat. 2001 Feb;4(1):22-8 [11512149.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1226-36 [10438710.001]
  • [Cites] N Engl J Med. 1988 Sep 22;319(12 ):745-52 [3137469.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3386-91 [9779717.001]
  • [Cites] JAMA. 1991 Sep 25;266(12 ):1672-7 [1886191.001]
  • [Cites] Cancer. 1987 Jan 1;59(1):38-42 [3539307.001]
  • [Cites] Med Pediatr Oncol. 1996 Feb;26(2):85-9 [8531858.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1318-32 [9193323.001]
  • [Cites] Haematologica. 2001 May;86(5):478-84 [11410410.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):406-13 [11466696.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):862-72; discussion 871-2 [9797699.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1677-82 [11896119.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3066-72 [11408503.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1416-34 [7888664.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Jan 28;288(6413):283-4 [6419896.001]
  • [Cites] J Clin Oncol. 1989 May;7(5):560-71 [2468745.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Aug 8;237(1):24-7 [9266822.001]
  • [Cites] Med Pediatr Oncol. 1994;23(6):493-6 [7935176.001]
  • [Cites] Br J Cancer. 2000 May;82(10):1636-45 [10817497.001]
  • [Cites] Life Sci. 2001 Jan 12;68(8):889-901 [11213359.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;46 Suppl:S18-22 [10950142.001]
  • [Cites] Drugs. 1998 Sep;56(3):385-403 [9777314.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):279-86 [8426205.001]
  • [Cites] J Clin Oncol. 1990 Nov;8(11):1806-10 [2230869.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):86-92 [9440727.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3273-9 [10986060.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):145-51 [1985164.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):2990-5 [3471321.001]
  • [Cites] N Engl J Med. 1996 May 30;334(22):1428-34 [8618581.001]
  • [Cites] Oncol Rep. 2001 May-Jun;8(3):611-4 [11295089.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1777-85 [7602367.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] Mol Biother. 1988;1(2):81-5 [3269251.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):657-63 [7165010.001]
  • [Cites] Med Pediatr Oncol. 1999 Mar;32(3):163-9 [10064182.001]
  • [Cites] Crit Rev Oncol Hematol. 1998 Aug;28(2):97-113 [9768345.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1717-21 [2317754.001]
  • [Cites] Cancer Res. 1983 Feb;43(2):546-50 [6848178.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):25-36 [11815957.001]
  • [Cites] In Vivo. 1993 Jan-Feb;7(1):17-26 [8504204.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3112-20 [8955656.001]
  • [Cites] Cancer. 1995 Dec 15;76(12):2557-64 [8625085.001]
  • [Cites] Klin Padiatr. 2002 Jan-Feb;214(1):22-9 [11823950.001]
  • [Cites] Blood. 2001 Jan 1;97(1):56-62 [11133742.001]
  • [Cites] Adv Exp Med Biol. 1999;457:621-9 [10500842.001]
  • [Cites] Curr Opin Mol Ther. 2001 Dec;3(6):567-78 [11804271.001]
  • [Cites] J Natl Cancer Inst. 1986 Aug;77(2):459-69 [3461207.001]
  • [Cites] Semin Hematol. 1999 Oct;36(4 Suppl 6):2-8 [10530710.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1726-34 [7564517.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1659-66 [8040678.001]
  • [Cites] Curr Opin Hematol. 2000 Jul;7(4):217-22 [10882177.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] Leukemia. 1997 Oct;11(10):1732-41 [9324295.001]
  • [Cites] Leukemia. 2000 Mar;14(3):356-63 [10720126.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 May-Jun;22(3):206-13 [10864051.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3244-54 [11432892.001]
  • [Cites] J Cancer Res Clin Oncol. 1998;124(3-4):207-14 [9619748.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):712-3 [11870257.001]
  • [Cites] Drug Intell Clin Pharm. 1985 Apr;19(4):259-64 [3891276.001]
  • [Cites] Pediatr Res. 1995 Nov;38(5):802-7 [8552452.001]
  • [Cites] Semin Oncol. 1998 Aug;25(4 Suppl 10):72-85 [9768828.001]
  • [Cites] Eur J Haematol. 2001 Mar;66(3):160-7 [11350484.001]
  • [Cites] Transplantation. 1992 Nov;54(5):829-33 [1440849.001]
  • [Cites] Cancer Treat Rep. 1978 Jun;62(6):887-91 [667863.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1215-23 [2045862.001]
  • [Cites] Med Pediatr Oncol. 2001 Aug;37(2):153-4 [11496359.001]
  • [Cites] Leukemia. 1998 May;12(5):675-81 [9593264.001]
  • [Cites] Cancer. 1993 May 15;71(10 Suppl):3392-9 [8490888.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1289-94 [11106118.001]
  • [Cites] Leukemia. 1992;6 Suppl 2:59-62 [1578943.001]
  • [Cites] Ann Intern Med. 1982 Feb;96(2):133-9 [7059060.001]
  • [Cites] BioDrugs. 1997 Jan;7(1):30-9 [18031078.001]
  • [Cites] Int J Clin Pharmacol Ther Toxicol. 1989 May;27(5):217-21 [2737789.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):916-24 [8164042.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1039-45 [8388919.001]
  • [Cites] Med Pediatr Oncol. 2000 Jul;35(1):52-63 [10881008.001]
  • [Cites] Blood. 2000 May 1;95(9):2770-5 [10779419.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1738-43 [7760889.001]
  • [Cites] Semin Oncol. 1982 Mar;9(1):23-33 [7071608.001]
  • [Cites] Ann Intern Med. 1983 Dec;99(6):745-9 [6651020.001]
  • [Cites] Blood. 1986 Nov;68(5):1114-8 [3533179.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Jan 28;288(6413):267-8 [6198019.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):99-108 [11905809.001]
  • [Cites] Toxicology. 1999 May 3;134(1):51-62 [10413188.001]
  • [Cites] Eur J Pediatr. 1980 Jun;134(1):87-90 [6997053.001]
  • [Cites] Drugs. 1999 Mar;57(3):293-308 [10193684.001]
  • [Cites] Blood. 2001 May 15;97(10):3197-204 [11342449.001]
  • [Cites] Cancer. 1987 Dec 15;60(12):2994-3000 [3479230.001]
  • [Cites] Eur J Pediatr. 1984 Dec;143(2):152-3 [6519114.001]
  • [Cites] Br J Haematol. 2002 May;117(2):333-42 [11972515.001]
  • [Cites] Br J Haematol. 1996 Jul;94(1):82-8 [8757513.001]
  • [Cites] Ann Hematol. 1993 Jan;66(1):33-43 [8431520.001]
  • [Cites] Drugs. 1987 Jul;34(1):1-24 [3308409.001]
  • [Cites] Int J Cancer. 1997 Mar 28;71(1):9-13 [9096658.001]
  • [Cites] Blood. 1995 Feb 15;85(4):1122-31 [7849300.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):10883-92 [11779855.001]
  • [Cites] Swiss Med Wkly. 2001 Apr 7;131(13-14):180-7 [11345808.001]
  • [Cites] Semin Oncol. 1992 Dec;19(6):670-86 [1462166.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2621-9 [7989937.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):100-9 [9792296.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):711-6 [9739435.001]
  • [Cites] Am J Med. 1985 Jul;79(1):43-8 [3860006.001]
  • [Cites] Lancet. 1987 Sep 12;2(8559):624-5 [2887906.001]
  • [Cites] Ann Hematol. 2001 Jul;80(7):417-22 [11529468.001]
  • [Cites] Drugs. 1993 May;45(5):737-59 [7686467.001]
  • [Cites] Herz. 2000 Nov;25(7):676-88 [11141677.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):935-42 [12006504.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1583-6 [9193356.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(4):465-71 [10855789.001]
  • [Cites] Am J Hematol. 1996 Sep;53(1):54-5 [8813107.001]
  • [Cites] Onkologie. 2001 Aug;24(4):326-30 [11574759.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1237-47 [10438711.001]
  • [Cites] J Clin Oncol. 1986 Mar;4(3):425-39 [3005521.001]
  • [Cites] Blood. 2000 Feb 1;95(3):790-4 [10648387.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • [Cites] Drugs. 2001;61(12):1765-74; discussion 1775-6 [11693465.001]
  • (PMID = 12452732.001).
  • [ISSN] 0114-5916
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Anthracyclines; 0 / Antimetabolites; 0 / Antineoplastic Agents; 0 / Glucocorticoids; 0 / Vinca Alkaloids; 30IQX730WE / Polyethylene Glycols; 5688UTC01R / Tretinoin; 7006-34-0 / Asparagine; 7D96IR0PPM / pegaspargase; EC 3.5.1.1 / Asparaginase; L36H50F353 / Podophyllotoxin
  • [Number-of-references] 172
  •  go-up   go-down


6. Trifunovic D, Vujisic-Tesic B, Vuckovic M, Ostojic M, Ristic A, Bogdanovic A, Mihaljevic B, Andjelic B, Perunicic-Jovanovic M, Antonic Z: Multimodality imaging in the assessment of cardiac lymphoma presented as new-onset atrial fibrillation. Echocardiography; 2010 Mar;27(3):332-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality imaging in the assessment of cardiac lymphoma presented as new-onset atrial fibrillation.
  • Cardiac involvement by non-Hodgkin's lymphoma is not uncommon, however rarely diagnosed during life due to nonspecific clinical presentation.
  • We report a case of secondary cardiac lymphoma in patient who presented with new-onset atrial fibrillation.
  • Cardiac lymphoma was in a form of bulky right atrial mass, infiltrating the atrial septum and cavo-atrial junction with concomitant mild pericardial effusion.
  • In the present case, we illustrate complementary role of transthoracic, transesophageal echocardiography and multislice CT scan with three-dimensional reconstruction, in detection and evaluation of secondary cardiac tumor.
  • Usefulness of echocardiography to follow up the effects of chemotherapy is also shown.
  • [MeSH-major] Atrial Fibrillation / ultrasonography. Echocardiography. Heart Neoplasms / secondary. Heart Neoplasms / ultrasonography. Lymphoma, Non-Hodgkin

  • MedlinePlus Health Information. consumer health - Atrial Fibrillation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20486963.001).
  • [ISSN] 1540-8175
  • [Journal-full-title] Echocardiography (Mount Kisco, N.Y.)
  • [ISO-abbreviation] Echocardiography
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Lather N, Islam M, Fergus IV: Symptomatic metastatic right atrial lymphoma in a patient with AIDS presenting with pulmonary embolization. Rev Cardiovasc Med; 2008;9(4):275-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptomatic metastatic right atrial lymphoma in a patient with AIDS presenting with pulmonary embolization.
  • Tumors involving the heart are rare, and the majority of them are benign.
  • Secondary lymphoma with localization to the heart is the third most common malignant heart tumor and is more common, by far, than primary cardiac lymphomas.
  • In patients with human immunodeficiency virus, the risk of development of systemic lymphoma is 60 to 200 times higher than in the general population.
  • Transthoracic echocardiography is the initial modality of choice for diagnosis of cardiac lymphomas because it is readily available and helps localize the tumor, but transesophageal echocardiography and magnetic resonance imaging remain the best tests for evaluation.
  • Treatment consists primarily of chemotherapy, and anticoagulation can be used in certain cases where embolization of the tumor is likely.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Heart Atria / pathology. Heart Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Pulmonary Embolism / virology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Echocardiography. Fatal Outcome. Humans. Male. Tomography, X-Ray Computed


8. Ueda K, Nagayama Y, Narita K, Kusano M, Mernyei M, Kamiya M: Pancreatic involvement by non-Hodgkin's lymphoma. J Hepatobiliary Pancreat Surg; 2000;7(6):610-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic involvement by non-Hodgkin's lymphoma.
  • A case of pancreatic involvement by non-Hodgkin's lymphoma is presented.
  • Therefore, pancreatoduodenectomy and right hemicolectomy were performed, although a definitive preoperative diagnosis was not obtained.
  • This tumor was identified, by histopathology and immunohistochemistry, as diffuse mixed type lymphoma with a B-cell phenotype.
  • Postoperatively, the patient had severe congestive heart failure, and he died without receiving chemotherapy.
  • It is important to establish a definitive diagnosis for this disease, to remove the tumor, and to treat the patient with appropriate chemotherapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Fatal Outcome. Heart Neoplasms / radiography. Heart Neoplasms / secondary. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11180896.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Rafajlovski S, Tatić V, Ilić S, Kanjuh V: [Frequency of metastatic tumors in the heart]. Vojnosanit Pregl; 2005 Dec;62(12):915-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Frequency of metastatic tumors in the heart].
  • INTRODUCTION: Secondary or metastatic tumors in the heart occur more frequently than primary ones, and, according to the published series, their frequency found in autopsic material ranges from 1.6% to 20.6%.
  • Metastatic tumors in the heart are rarely clinically symptomatic, and, therefore, they are rarely diagnosed within the lifetime.
  • The aim of this study was to analyze the frequency of metastatic tumors of the heart, their primary localization, as well as the localization of the metastases found in the autopsic material within the period 1972-2004.
  • METHODS: During the autopsy of the patients died of metastatic tumors, we microscopically and macroscopically analyzed all the organs and tissues to determine the metastases of primary tumors in other organs, especially in the heart and pericardium.
  • In 2 928 (25.6%) out of 11 403 autopsies, the presence of malignant tumor was diagnosed, and in 79 (2.7%) of these cases, metastasis of the heart was found out.
  • Only in 5 of the cases, the presence of metastasis in the heart was diagnosed during the lifetime.
  • The most frequent metastases in the heart were caused by pulmonary carcinoma (18 cases), leukemia and malignant lymphoma (8 cases, each), then pancreatic and breast carcinoma, while the metastases of other carcinomas were rather rare.
  • CONCLUSION: Metastatic tumors of the heart are rather rare, and rarely clinically symptomatic, and, thus, rarely diagnosed during life.
  • The methods of choice for the diagnosis of the metastasis in the heart are echocardiography, computerized tomography, magnetic resonance imaging, cytological analysis of the pericardial effusion and biopsy.
  • The treatment includes surgery, chemotherapy and radiotherapy.
  • [MeSH-major] Heart Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16375220.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


10. Cho JG, Ahn YK, Cho SH, Lee JJ, Chung IJ, Park MR, Kim HJ, Jeong MH, Park JC, Kang JC: A case of secondary myocardial lymphoma presenting with ventricular tachycardia. J Korean Med Sci; 2002 Aug;17(4):549-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of secondary myocardial lymphoma presenting with ventricular tachycardia.
  • Malignant lymphoma can involve the cardiac cavity or myocardium as a mass.
  • Clinical symptoms of its cardiac involvement are usually absent or nonspecific, making the diagnosis of the cardiac involvement very difficult before death.
  • We experienced a patient with secondary myocardial non-Hodgkin's lymphoma presenting with sustained ventricular tachycardia (VT) as a primary clinical problem.
  • Physical examination revealed rapid heart beat with variable intensity of the first heart sound and soft mass in the lower abdomen.
  • Cytological examination of aspirated pericardial fluid and percutaneous needle biopsy of the abdominal mass revealed a diffuse large cell type non-Hodgkin's lymphoma.
  • Myocardial masses and ventricular tachycardia resolved with chemotherapy using cyclophosphamide, adriamycin, vincristine and prednisone regimen.
  • [MeSH-major] Heart Neoplasms / pathology. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / pathology. Myocardium / pathology. Tachycardia, Ventricular / etiology
  • [MeSH-minor] Abdominal Neoplasms / secondary. Adult. Biopsy, Needle. Bundle-Branch Block. Echocardiography. Electrocardiography. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12172054.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3054895
  •  go-up   go-down


11. Manojkumar R, Sharma A, Grover A: Secondary lymphoma of the heart presenting as recurrent syncope. Indian Heart J; 2001 Mar-Apr;53(2):221-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary lymphoma of the heart presenting as recurrent syncope.
  • Left cervical lymph node biopsy confirmed the diagnosis of non-Hodgkin's lymphoma.
  • The tumor resolved completely with chemotherapy without surgical intervention.
  • [MeSH-major] Heart Neoplasms / complications. Heart Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / diagnosis. Syncope / etiology
  • [MeSH-minor] Amiodarone / administration & dosage. Antineoplastic Combined Chemotherapy Protocols. Child. Cyclophosphamide. Doxorubicin. Echocardiography, Transesophageal. Electrocardiography. Follow-Up Studies. Humans. Male. Prednisolone. Recurrence. Tachycardia, Ventricular / etiology. Tomography, X-Ray Computed. Treatment Outcome. Vincristine

  • MedlinePlus Health Information. consumer health - Fainting.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11428484.001).
  • [ISSN] 0019-4832
  • [Journal-full-title] Indian heart journal
  • [ISO-abbreviation] Indian Heart J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; N3RQ532IUT / Amiodarone; VAP-cyclo protocol
  •  go-up   go-down


12. Matkowskyj KA, Wiseman WR, Robin JC, Norvell JP, Puthumana J, Nelson B, Peterson L, McGarry TJ, Tourtellotte WG: Therapy-related myelodysplastic syndrome presenting as fulminant heart failure secondary to myeloid sarcoma. J Hematop; 2010;3(1):41-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related myelodysplastic syndrome presenting as fulminant heart failure secondary to myeloid sarcoma.
  • Rapidly progressive heart failure is commonly caused by an extensive myocardial infarction, a mechanical complication of infarction, myocarditis, or acute valvular insufficiency.
  • The patient presented with episodic shortness of breath, he was anemic and thrombocytopenic, and his bone marrow biopsy revealed myelodysplastic syndrome from treatment for oligodendroglioma.
  • His clinical course was characterized by a chronic leak of cardiac enzymes, a new right bundle branch block, and a large pericardial effusion causing tamponade and death from fulminant heart failure and ventricular arrhythmias within 2 weeks.
  • At autopsy, the heart was massively infiltrated with myeloblasts and other immature myeloid cells.
  • Cardiac infiltration in a patient with myelodysplastic syndrome is extremely rare, especially in the absence of bone marrow involvement by blasts.
  • The recognition of this entity is becoming increasingly important as the incidence of cardiac myeloid sarcoma may be on the rise as the number of patients receiving chemotherapy increases.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cardiol. 2001 Oct;38(4):219-24 [11688429.001]
  • [Cites] Acta Cardiol. 2003 Apr;58(2):155-8 [12715908.001]
  • [Cites] Echocardiography. 2003 Aug;20(6):539-44 [12859368.001]
  • [Cites] Cancer. 1965 Feb;18:253-8 [14254082.001]
  • [Cites] BMC Blood Disord. 2006;6:4 [16953890.001]
  • [Cites] Am J Hematol. 1987 Jul;25(3):325-32 [3300284.001]
  • [Cites] Am J Surg Pathol. 1993 Oct;17(10):1011-9 [8372941.001]
  • [Cites] Med Clin (Barc). 1996 Apr 13;106(14):545-7 [8656744.001]
  • [Cites] J Am Soc Echocardiogr. 2004 Sep;17(9):1000-2 [15337968.001]
  • [Cites] Eur J Nucl Med. 1992;19(4):306-8 [1597247.001]
  • [Cites] Leuk Lymphoma. 2005 Jul;46(7):1081-4 [16019562.001]
  • [Cites] Acta Pathol Jpn. 1990 Dec;40(12):922-6 [2096594.001]
  • [Cites] Arch Pathol Lab Med. 1990 Sep;114(9):983-5 [2390016.001]
  • [Cites] N Engl J Med. 1990 Feb 1;322(5):337-8 [2404207.001]
  • [Cites] Pediatr Hematol Oncol. 1987;4(3):237-45 [3152929.001]
  • [Cites] Am J Cardiol. 1968 Mar;21(3):388-412 [4295426.001]
  • [Cites] Cancer. 1973 Apr;31(4):948-55 [4513297.001]
  • [Cites] Am J Clin Pathol. 1995 Oct;104(4):431-43 [7572794.001]
  • (PMID = 21544187.001).
  • [ISSN] 1865-5785
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Grant] United States / NIH HHS / OD / K26 OD010945
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2883902
  • [Keywords] NOTNLM ; Leukemia cordis / Myeloid sarcoma / Rapidly progressive heart failure / Therapy-related myelodysplastic syndrome
  •  go-up   go-down


13. Chow LM, Nathan PC, Hodgson DC, Jenkin D, Weitzman S, Grant RM, Manson D, Bross A, Doyle JJ, Danjoux C, Greenberg ML: Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. J Clin Oncol; 2006 Dec 20;24(36):5735-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
  • PURPOSE: Reduced-intensity protocols for pediatric Hodgkin's lymphoma are aimed at preserving excellent relapse-free survival while decreasing the incidence of late effects.
  • PATIENTS AND METHODS: We retrospectively reviewed the outcome of 123 children treated consecutively for Hodgkin's lymphoma at a single institution.
  • Patients with stages I-IIIB disease received three cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)/ doxorubicin, bleomycin, and vinblastine (ABV) followed by 15 Gy of extended-field irradiation, while those with stage IV disease were treated with six to eight cycles of MOPP/ABV chemotherapy with or without radiotherapy.
  • RESULTS: At a median follow-up of 8.5 years (range, 1.4 to 15.5 years), the estimated 10-year overall survival and event-free survival are 94% (SE, 2.2%) and 88% (SE, 3.1%) respectively.
  • There have been 12 treatment failures and six disease-related deaths.
  • A very large mediastinal mass ( 50% of the maximal thoracic diameter) was associated with a 10-year event-free survival of 50% (SE, 14%) compared with 91% (SE, 4.0%) for smaller masses (P < .001).
  • There have been no cases of secondary leukemia and four secondary solid malignancies observed to date.
  • CONCLUSION: MOPP/ABV and low-dose, extended-field radiotherapy is an effective treatment for pediatric Hodgkin's lymphoma.
  • With median follow-up of 8.5 years, late cardiopulmonary effects and secondary malignancies from this treatment regimen are infrequent.
  • Continued longitudinal observations, particularly for breast cancer in female patients and gonadotoxicity, will determine whether the goal of decreasing treatment-related complications while maintaining excellent survival has been achieved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Bleomycin / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Heart / drug effects. Humans. Hypothyroidism / etiology. Infant. Lung / drug effects. Male. Mechlorethamine / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179107.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; MOPP-ABV protocol
  •  go-up   go-down


14. Rubiales AS, Reyes A, Renedo AF, Torrego JC, Puertas J, Marcos G: Heart metastases and superior vena cava syndrome. Clin Transl Oncol; 2007 Aug;9(8):540-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heart metastases and superior vena cava syndrome.
  • The first one was secondary to solitary atrial metastases of rectal adenocarcinoma and benefited from palliative chemotherapy.
  • The second patient had a disseminated large cell B-cell lymphoma with rapid clinical complete response, but she eventually died after relapse.
  • [MeSH-major] Heart Atria. Heart Neoplasms / secondary. Superior Vena Cava Syndrome / etiology
  • [MeSH-minor] Adenocarcinoma / secondary. Adult. Aged. Female. Humans. Lymphoma, B-Cell / pathology. Radiography

  • Genetic Alliance. consumer health - Superior vena cava syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Hematol. 1999 Oct;70(3):174-7 [10561910.001]
  • [Cites] Clin Nucl Med. 1989 Sep;14 (9):698-9 [2791428.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2003 Jul;51(7):330-2 [12892468.001]
  • [Cites] Am Heart J. 1994 Feb;127(2):465-8 [8296725.001]
  • [Cites] Orv Hetil. 1991 Mar 24;132(12):639-41 [2011388.001]
  • [Cites] Echocardiography. 2002 Jan;19(1):61-2 [11884256.001]
  • [Cites] Ann Med Interne (Paris). 1987;138(8):672-4 [3450219.001]
  • [Cites] Intern Med. 2000 Feb;39(2):139-42 [10732831.001]
  • [Cites] J Am Soc Echocardiogr. 1990 Mar-Apr;3(2):149-53 [2185795.001]
  • [Cites] Magn Reson Imaging. 1998;16(1):91-5 [9436953.001]
  • (PMID = 17720658.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Patel TM, Shah SC, Ranjan A, Malhotra H, Patel R, Gupta AK: Stenting through a portacath for totally occluded superior vena cava in a case of non-Hodgkin s lymphoma. J Invasive Cardiol; 2003 Feb;15(2):86-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stenting through a portacath for totally occluded superior vena cava in a case of non-Hodgkin s lymphoma.
  • Percutaneous intervention is the treatment of choice.
  • We report a case of SVC stenting in a middle-aged woman with SVC obstruction secondary to portacath insertion for chemotherapy.
  • [MeSH-major] Catheters, Indwelling / adverse effects. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / drug therapy. Stents. Superior Vena Cava Syndrome / etiology. Superior Vena Cava Syndrome / surgery
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Vessel Prosthesis Implantation. Female. Humans

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12556622.001).
  • [ISSN] 1042-3931
  • [Journal-full-title] The Journal of invasive cardiology
  • [ISO-abbreviation] J Invasive Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Allegra A, Alonci A, Russo S, Cannavò A, Penna G, D'Angelo A, Bellomo G, Musolino C: Cardiac involvement in patients with hematologic malignancies. J Investig Med; 2010 Oct;58(7):859-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac involvement in patients with hematologic malignancies.
  • Authors have reviewed literature about the management of patients with cardiologic disease occurring secondary to hematologic pathology itself or its therapy, with a focus on infiltration of myocardium in acute and chronic leukemia, lymphoma, multiple myeloma, and hypereosinophilic syndrome.
  • Moreover, they evaluated chemotherapy-associated toxicity, particularly for new drugs such as monoclonal antibody therapy, tyrosine kinase inhibitors, arsenic trioxide, bortezomib, and epigenetic therapy.
  • In fact, cardiac toxicity may range from asymptomatic subclinical abnormalities, such as electrocardiographic changes and left ventricular ejection decline, to life-threatening events and lead to chemotherapy dose reduction and delay and, in some cases, for patients with severe side effects, discontinuation of treatment.
  • Finally, they discussed on the identification of early markers of cardiac injury and on cardiac stem cell therapy as a promising approach to facilitate myocardial regeneration.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Heart Diseases / chemically induced. Heart Diseases / complications. Hematologic Neoplasms / complications. Hematologic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683345.001).
  • [ISSN] 1708-8267
  • [Journal-full-title] Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  • [ISO-abbreviation] J. Investig. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Radcliffe RW, Paglia DE, Couto CG: Acute lymphoblastic leukemia in a juvenile southern black rhinoceros (Diceros bicornis minor). J Zoo Wildl Med; 2000 Mar;31(1):71-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 21-mo-old female southern black rhinoceros (Diceros bicornis minor) developed acute upper respiratory dyspnea in association with lymphadenopathy and marked immature lymphocytosis.
  • Antineoplastic chemotherapy included administration of cytarabine, cyclophosphamide, vincristine, and doxorubicin, with clinical remission achieved 19 days after initiation of treatment.
  • The rhinoceros died, however, of congestive heart failure, presumably secondary to doxorubicin cardiotoxicity and a particular sensitivity of rhinoceros myocardial tissue to free hydroxyl radicals.
  • The pharmacologic effects of any therapeutic agent need to be carefully considered before use in the black rhinoceros, especially within the context of the unique physiology of this species.
  • [MeSH-major] Perissodactyla. Precursor Cell Lymphoblastic Leukemia-Lymphoma / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10884128.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  •  go-up   go-down


18. Durrleman N, El Hamamsy I, Demaria R, Carrier M, Perrault LP, Albat B: [Is Dacron carcinogenic? Apropos of a case and review of the literature]. Arch Mal Coeur Vaiss; 2004 Mar;97(3):267-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary malignant cardiac tumours are extremely rare.
  • The authors report a case of primary cardiac lymphoma nine years after implantation of a double leaflet mitral valve prosthesis.
  • Malignant lymphoma is a haematological form of sarcoma.
  • It typically presents as a nodular or diffuse myocardial infiltrate explaining its clinical expression as cardiac failure and atrioventricular block.
  • Survival after "pure" medical therapy (chemotherapy alone or associated with radiotherapy) is 6 to 8 months after diagnosis.
  • Dacron has been implicated in the pathogenesis of primary cardiac sarcoma.
  • In conclusion, although primary cardiac lymphoma is a rare condition, it should be considered, as with thrombosis, a possible differential diagnosis of acute dysfunction of cardiac valvular prostheses.
  • [MeSH-major] Heart Neoplasms / etiology. Heart Valve Prosthesis / adverse effects. Lymphoma, Large-Cell, Immunoblastic / etiology. Polyethylene Terephthalates / adverse effects
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / secondary. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asthenia / etiology. Diagnostic Errors. Fatal Outcome. Female. Humans. Mitral Valve / surgery. Multiple Organ Failure / etiology. Myxoma / diagnosis. Sarcoma / chemically induced. Thrombosis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15106752.001).
  • [ISSN] 0003-9683
  • [Journal-full-title] Archives des maladies du coeur et des vaisseaux
  • [ISO-abbreviation] Arch Mal Coeur Vaiss
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Polyethylene Terephthalates
  • [Number-of-references] 10
  •  go-up   go-down


19. Avilés A, Delgado S, Fernández R, Talavera A, Neri N, Huerta-Guzmán J: Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. Eur J Haematol; 2002 Mar;68(3):144-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial.
  • OBJECTIVES: We evaluate the long-term results of a randomized clinical trial in patients with advanced stages (III and IV) of follicular lymphoma using chemotherapy or combined therapy (chemotherapy following by adjuvant radiotherapy in patients with nodal bulky disease).
  • MATERIAL AND METHODS: Between 1981 and 1995, patients with follicular lymphoma were treated with combined chemotherapy, mostly anthracycline-based regimens; patients who achieved complete response were randomly assigned either to receive adjuvant radiotherapy to sites or to nodal bulky disease or not (control group).
  • Acute and late toxicity were minimal; only four patients (<1%) developed myelodysplastic syndrome/acute leukemia.
  • Cardiac toxicity was 2%, but one case was lethal.
  • Thirty-six patients (8%) died secondary to unrelated causes, in complete remission.
  • CONCLUSIONS: The use of adjuvant radiotherapy in patients with poor-prognosis follicular lymphoma increases EFS and OS with minimal toxicity.
  • We feel that follicular lymphoma should be treated curatively because <80% of patients will be in first complete response at <20yr.
  • The use of adjuvant radiotherapy will be considered in the first line of treatment in this set of patients.
  • [MeSH-major] Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cause of Death. Combined Modality Therapy. Disease-Free Survival. Female. Heart Diseases / chemically induced. Humans. Male. Middle Aged. Myocardial Infarction / chemically induced. Neoplasm Staging. Prognosis. Recurrence. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12068794.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Denmark
  •  go-up   go-down


20. Van Der Klooster JM, Van Der Wiel HE, Van Saase JL, Grootendorst AF: Asystole during combination chemotherapy for non-Hodgkin's lymphoma: the acute tumor lysis syndrome. Neth J Med; 2000 Apr;56(4):147-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asystole during combination chemotherapy for non-Hodgkin's lymphoma: the acute tumor lysis syndrome.
  • It is characterized by the development of hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, acute renal failure and metabolic acidosis, as a result of massive tumor cell destruction, usually secondary to effective cytotoxic treatment.
  • We want to present the case history of a 62-year-old woman who died from cardiorespiratory arrest during combination chemotherapy for non-Hodgkin's lymphoma due to acute tumor lysis syndrome.
  • Despite general preventive measures, severe electrolyte abnormalities developed within 18 h of the start of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphoma, Large B-Cell, Diffuse / drug therapy. Tumor Lysis Syndrome / etiology
  • [MeSH-minor] Cyclophosphamide / adverse effects. Doxorubicin / adverse effects. Fatal Outcome. Female. Heart Arrest / etiology. Humans. Middle Aged. Prednisone / adverse effects. Vincristine / adverse effects

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neth J Med. 2001 Aug;59(2):83-5 [11550657.001]
  • (PMID = 10727760.001).
  • [ISSN] 0300-2977
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


21. Johri A, Baetz T, Isotalo PA, Nolan RL, Sanfilippo AJ, Ropchan G: Primary cardiac diffuse large B cell lymphoma presenting with superior vena cava syndrome. Can J Cardiol; 2009 Jun;25(6):e210-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac diffuse large B cell lymphoma presenting with superior vena cava syndrome.
  • Primary cardiac lymphomas are rare extranodal lymphomas that should be distinguished from secondary cardiac involvement by disseminated non-Hodgkin's lymphoma.
  • Cardiac lymphomas often mimic other cardiac neoplasms, including myxomas and angiosarcomas, and often require multimodality cardiac imaging, in combination with endomyocardial biopsy, excisional biopsy or pericardial fluid cytology, to establish a definitive diagnosis.
  • A 60-year-old immunocompetent man who presented with superior vena cava syndrome secondary to a right atrial, primary cardiac diffuse large B cell lymphoma (non-Hodgkin's lymphoma) is described in the present article.
  • The patient had no clinical evidence of disseminated lymphoma and was successfully treated with prompt surgical excision of his atrial mass, followed by anthracycline-based chemotherapy.
  • The patient required multi-modality cardiac imaging to accurately identify and plan surgical excision of his cardiac lymphoma.
  • The therapeutic management and clinical and radio-logical features of primary cardiac lymphoma are reviewed.
  • [MeSH-major] Heart Neoplasms / complications. Lymphoma, Large B-Cell, Diffuse / complications. Superior Vena Cava Syndrome / etiology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Superior vena cava syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 Oct 15;80(8):1497-506 [9338475.001]
  • [Cites] Cardiovasc Pathol. 2009 Mar-Apr;18(2):92-9 [18402841.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1344-50 [17721189.001]
  • (PMID = 19536397.001).
  • [ISSN] 1916-7075
  • [Journal-full-title] The Canadian journal of cardiology
  • [ISO-abbreviation] Can J Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2722499
  •  go-up   go-down


22. Gaspar A, Salomé N, Nabais S, Brandão A, Simões A, Portela C, Salgado A, Pereira A, Correia A: Echocardiographic assessment of a cardiac lymphoma: beyond two-dimensional imaging. Eur J Echocardiogr; 2009 Dec;10(8):975-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Echocardiographic assessment of a cardiac lymphoma: beyond two-dimensional imaging.
  • Lymphoma is usually recognized as the third most frequent metastatic malignancy involving the heart.
  • In recent years, the incidence of cardiac lymphoma has increased, mainly because of HIV-infected patients.
  • We present a case of secondary cardiac lymphoma in an HIV patient presenting with heart failure.
  • Doppler tissue imaging (DTI) showed reduced systolic and diastolic velocities at mitral and tricuspid annulus, compatible with systolic and diastolic myocardial dysfunction, likely owing to infiltration.
  • After 2 weeks of chemotherapy, repeated exam showed significant reduction of the tumour mass and of the LV wall thickness, as well as normalized systolic and diastolic velocities at mitral and tricuspid annulus, as assessed by DTI.
  • Use of transthoracic echocardiography, mostly two-dimensional imaging, has been described for several years for the diagnosis of cardiac involvement as well as for the assessment of tumour regression in response to chemotherapy.
  • The present case report highlights the potential utility of other echocardiographic modalities, particularly DTI, for the assessment of cardiac lymphoma but also for monitoring the tumour response to adequate therapy.
  • [MeSH-major] Echocardiography / methods. Heart Neoplasms / ultrasonography. Lymphoma / ultrasonography
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. HIV Infections / complications. Humans. Male

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19570800.001).
  • [ISSN] 1532-2114
  • [Journal-full-title] European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
  • [ISO-abbreviation] Eur J Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Avilés A, Nambo MJ, Neri N, Talavera A, Castañeda C, Murillo E, Cleto S, Huerta-Guzmán J: Intensive chemotherapy in the treatment of aggressive diffuse large B-cell lymphoma: malignant lymphoma. Med Oncol; 2004;21(3):269-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy in the treatment of aggressive diffuse large B-cell lymphoma: malignant lymphoma.
  • The aim of the present study was to evaluate an intensive chemotherapy regimen in patients with diffuse large B-cell lymphoma and poor prognosis, as presence of high- or high-intermediate clinical risk, bulky disease, high levels of beta 2 microgloblin, and more than two extranodal sites of involvement at diagnosis.
  • Five died secondary to tumor progression, actuarial curves at 3-yr for overall survival were 75%.
  • Toxicity was mild, granulocytopenia grade III or IV were observed in the 46% of the cycles; infection-related granulocytopenia was observed in 17%, but no fatality due to therapy was observed.
  • Cardiac toxicity was mild, only seven patients showed a drop in left ejection ventricular function, but no symptomatic heart failure has been observed.
  • The intensive CEOP-Bleo regimen with increasing doses of cyclophosphamide and epirubicin is a useful and well-tolerated regimen in the treatment of poor prognosis diffuse large B-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Epirubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Prognosis. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Ann Intern Med. 1985 May;102(5):596-602 [2580468.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):651-6 [7694634.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2282-8 [9610711.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1018-26 [2474057.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):25-38 [1702144.001]
  • [Cites] N Engl J Med. 1997 May 1;336(18):1290-7 [9113932.001]
  • [Cites] Ann Intern Med. 1986 Jun;104(6):757-65 [2422995.001]
  • [Cites] N Engl J Med. 1992 Nov 5;327(19):1342-9 [1383819.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3564-73 [8260695.001]
  • [Cites] Hematol J. 2001;2(4):279-85 [11920261.001]
  • [Cites] J Clin Oncol. 1991 Feb;9(2):339-47 [1824863.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1275-81 [8648384.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2916-23 [8523055.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1309-15 [10715302.001]
  • (PMID = 15456955.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


24. Pacifico N, Weishaar KM, Boozer LB, Nakamura RK: Full recovery after cardiac arrest secondary to accidental iatrogenic venous air embolism in a cat. J Vet Emerg Crit Care (San Antonio); 2010 Apr 1;20(2):264-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Full recovery after cardiac arrest secondary to accidental iatrogenic venous air embolism in a cat.
  • OBJECTIVE: To describe the successful management of cardiac arrest following accidental venous air embolism (VAE) in a cat.
  • CASE SUMMARY: A 3-year-old spayed female domestic shorthair cat, weighing 4 kg, was presented for continuation of its chemotherapy protocol.
  • The cat was inadvertently administered approximately 5.5 mL of air IV during initiation of fluid therapy.
  • Immediate cardiac arrest resulted and CPR successfully achieved return of spontaneous circulation.
  • This is the first report of a cat surviving cardiac arrest secondary to VAE.
  • [MeSH-major] Cat Diseases / therapy. Embolism, Air / veterinary. Fluid Therapy / veterinary. Heart Arrest / veterinary. Iatrogenic Disease / veterinary
  • [MeSH-minor] Animals. Cardiopulmonary Resuscitation / veterinary. Cats. Female. Lymphoma, Non-Hodgkin / therapy. Lymphoma, Non-Hodgkin / veterinary. Oxygen Inhalation Therapy / methods. Oxygen Inhalation Therapy / veterinary. Treatment Outcome. Veins

  • MedlinePlus Health Information. consumer health - Cardiac Arrest.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20487256.001).
  • [ISSN] 1476-4431
  • [Journal-full-title] Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
  • [ISO-abbreviation] J Vet Emerg Crit Care (San Antonio)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Prunier F, Revel F, Hemery Y, Glaser E, Beaufils P: [Malignant non-Hodgkin's lymphoma presenting with arrhythmia and conduction defects. Report of 2 cases]. Arch Mal Coeur Vaiss; 2000 Nov;93(11):1333-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant non-Hodgkin's lymphoma presenting with arrhythmia and conduction defects. Report of 2 cases].
  • Primary cardiac lymphoma is very rare.
  • Secondary localisations are more common, observed in 15 to 30% of autopsy series.
  • Clinical symptoms of cardiac involvement are rare, explaining the usual post-mortem diagnosis.
  • The presentation of cardiac involvement by arrhythmias and conduction defects is very uncommon.
  • The authors report two cases, the first of a 35 year old man in whom primary cardiac lymphoma presented with ventricular tachycardia complicated secondarily by complete atrioventricular block (AVB) with pseudo-inferior wall infarction.
  • The second case was a 37 year old man with a cutaneous T cell lymphoma in whom complete AVB was the first sign of a secondary cardiac localisation of his disease.
  • The finding of cardiac lymphoma should lead to aggressive chemotherapy as soon as possible.
  • [MeSH-major] Heart Block / etiology. Heart Neoplasms / secondary. Lymphoma, Non-Hodgkin / complications. Tachycardia, Ventricular / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11190461.001).
  • [ISSN] 0003-9683
  • [Journal-full-title] Archives des maladies du coeur et des vaisseaux
  • [ISO-abbreviation] Arch Mal Coeur Vaiss
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


26. Barbaric D, Holley D, Lau KC, McCowage G: It is ALL in the heart: a patient with acute lymphoblastic leukemia and cardiac infiltration at time of diagnosis. Leuk Lymphoma; 2002 Dec;43(12):2417-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] It is ALL in the heart: a patient with acute lymphoblastic leukemia and cardiac infiltration at time of diagnosis.
  • We report an unusual case of acute lymphoblastic leukemia (ALL) in a 15-year-old boy where a mass lesion, presumed to be a cardiac metastasis, was noted in the right ventricular wall and cavity at the time of initial routine echocardiography.
  • The lesion resolved, without surgical intervention, following the institution of multi-agent chemotherapy.
  • [MeSH-major] Heart Neoplasms / secondary. Leukemic Infiltration. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Brain Neoplasms / diagnosis. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Cerebrospinal Fluid / cytology. Combined Modality Therapy. Disease-Free Survival. Electrocardiography. Humans. Immunophenotyping. Male. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613535.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. von der Weid NX: Adult life after surviving lymphoma in childhood. Support Care Cancer; 2008 Apr;16(4):339-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult life after surviving lymphoma in childhood.
  • The combined incidence of Hodgkin's disease (HD) and non-Hodgkin lymphoma (NHL) reaches 10 to 12 new cases a year per million children under the age of 16 years, representing about 10% of all pediatric cancers.
  • Intrathecal or high-dose intravenous chemotherapy with methotrexate may induce the same problems, although in a lesser extent and severity.
  • Cardiac function must be serially evaluated over the long to very long-term because of potential cardiomyopathy after high anthracycline doses and/or mediastinal irradiation.
  • Radiation therapy to the neck and mediastinum (mantle field) induces a 50% risk of developing hypothyroidism and a 20% risk of developing thyroid nodules at 20 years.
  • The risk of thyroid cancer is 18 times higher the expected rate for the general population.
  • Secondary aggressive breast cancer shows a cumulative risk of 30% at 30 years after radiotherapy.
  • Other structures affected by mediastinal irradiation are the heart (pericardial, myocardial and endocardial structures), the great arteries (fibrosis, stenosis, aneurysms) and the central portion of the lungs (diffusion troubles, restrictive pneumopathy).
  • Cardiac toxicity can be enhanced by the concomitant therapy with adriamycin and lung toxicity by bleomycin.
  • Radiotherapy to the paraaortic and iliacal lymph nodes can affect gonadal function both in males and females; concomitant chemotherapy with alkylating agents like cyclophosphamide and especially procarbazine have a synergistic action and can lead to premature menopause as well as infertility.
  • Although the vast majority of survivors from pediatric lymphomas fare well, a minority present with extreme symptoms of depression and psychosomatic distress; female sex, low socio-economic status and treatment with intensive chemotherapy are important risk factors for a poor psychosocial outcome.
  • A well functioning network of pediatric oncologists, GP's, adult oncologists and other specialists of adult medicine must be developed in order to prevent, early detect and treat expected long-term toxicities.
  • [MeSH-major] Lymphoma. Radiotherapy / adverse effects. Survivors

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Dec;9(12):1990-6 [8609707.001]
  • [Cites] Cancer. 1976 Dec;38(6):2263-8 [826312.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] N Engl J Med. 1981 Jun 4;304(23):1377-82 [7231460.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13176-81 [9789061.001]
  • [Cites] Cancer Treat Rep. 1982 Apr;66(4):977-89 [7074658.001]
  • [Cites] Pediatrics. 2002 Jul;110(1 Pt 1):42-52 [12093945.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Jan;27(1):28-36 [15654275.001]
  • [Cites] Med Pediatr Oncol. 1996 Aug;27(2):74-8 [8649323.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):191-6 [11134212.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] J Pediatr. 1993 Jul;123(1):59-64 [8320626.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):145-51 [1985164.001]
  • [Cites] Med Pediatr Oncol. 1997 Jun;28(6):387-400 [9143382.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4091-5 [11051261.001]
  • [Cites] Ann Neurol. 1999 Dec;46(6):834-41 [10589535.001]
  • [Cites] Pharmacogenetics. 2002 Nov;12(8):605-11 [12439220.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):819-29 [12123328.001]
  • [Cites] Blood. 1996 Apr 1;87(7):3045-52 [8639928.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5735-41 [17179107.001]
  • [Cites] N Engl J Med. 1988 Jan 14;318(2):76-81 [3336397.001]
  • [Cites] Cancer. 1981 May 15;47(10):2368-74 [6791800.001]
  • [Cites] J Clin Oncol. 1984 Jun;2(6):571-7 [6547167.001]
  • [Cites] Am J Obstet Gynecol. 1992 Mar;166(3):788-93 [1550144.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1208-15 [8315419.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):569-77 [10080601.001]
  • [Cites] Swiss Med Wkly. 2001 Apr 7;131(13-14):180-7 [11345808.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2435-43 [10856104.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):873-80 [2211255.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):345-59 [12877662.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):359-65 [12565989.001]
  • [Cites] J Pediatr. 1993 Oct;123(4):546-52 [8410505.001]
  • [Cites] JAMA. 1979 Oct 26;242(17):1877-81 [480620.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):233-55 [9748598.001]
  • (PMID = 18196290.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


28. Pinkerton CR, Hann I, Weston CL, Mapp T, Wotherspoon A, Hobson R, Kelly DA, Vergani D, Hadzic D, Rees L, Burke M, Alero Thomas J: Immunodeficiency-related lymphoproliferative disorders: prospective data from the United Kingdom Children's Cancer Study Group Registry. Br J Haematol; 2002 Aug;118(2):456-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical data and biological samples were prospectively collected in 42 children with lymphoproliferative disease (LPD) secondary to organ/bone marrow transplant-related immunosuppression (30: 11 liver, 10 heart/lung, 8 kidney and 1 bone marrow), other drug-induced immunosuppression (2), congenital immunodeficiency (8) or human immunodeficiency virus (HIV)-related immune dysfunction (2).
  • Pathology was centrally reviewed and showed polymorphic features in 5 cases, monomorphic in 23, mixed pattern in 5 patients and 9 other types.
  • Using the Pittsburgh classification, 9 were lymphadenopathic, 10 were systemic, 25 were lymphomatous and, with the Murphy grouping for non-Hodgkin's lymphoma (NHL), 10 were localized and 32 non-localized.
  • Nineteen patients received chemotherapy, 14/18 evaluable responded, which was sustained in 8 cases.
  • In the transplant group close monitoring of response during reduction in immunosuppression is essential and the early use of B NHL chemotherapy may be effective.
  • [MeSH-major] Immunologic Deficiency Syndromes / therapy. Lymphoproliferative Disorders / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation / methods. Bone Marrow Transplantation / mortality. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Female. Great Britain / epidemiology. Humans. Immunosuppressive Agents / therapeutic use. Infant. Liver Transplantation / methods. Liver Transplantation / mortality. Prospective Studies. Registries

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12139732.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


29. Kholová I, Kautzner J: Current treatment in cardiac amyloidosis. Curr Treat Options Cardiovasc Med; 2006 Dec;8(6):468-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment in cardiac amyloidosis.
  • Involvement of the heart is a common finding in amyloidosis.
  • The heart is usually infiltrated by amyloid fibrils in primary amyloidosis and age-related forms of amyloidosis, less commonly in transthyretin familial amyloidosis, and rarely in secondary amyloidosis.
  • The most common clinical presentation is restrictive cardiomyopathy with right-sided heart failure.
  • The second most frequent presentation is congestive heart failure due to systolic dysfunction, followed by arrhythmias and orthostatic hypotension.
  • The diagnosis of amyloidosis requires tissue sample confirmation; at present, Congo red staining in polarized light is the diagnostic method of choice.
  • The characterization of protein fibril type by immunohistochemistry or biochemistry is essential for patient prognosis and treatment.
  • The therapeutic approach consists of specific treatment of amyloidosis and supportive treatment for cardiac-related symptoms.
  • The treatment depends on the type of amyloidosis and the stage of disease.
  • The mainstay of supportive treatment of cardiac failure is diuretic therapy.
  • Primary amyloidosis treatment protocol includes melphalan and prednisone chemotherapy.
  • Heart transplantation is only a palliative treatment.
  • Stem cell transplantation is an emerging treatment alternative.
  • Combination therapy of melphalan and stem cell transplantation has been shown to be a promising treatment strategy.
  • Secondary amyloidosis requires aggressive treatment of the associated inflammatory and neoplastic process.
  • Age-related (senile) amyloidosis benefits from supportive cardiac treatment when applicable.
  • Transthyretin amyloidosis, the most common cardiac hereditary amyloidosis, is treated by liver or combined liver-heart transplantation.
  • New therapies based on chemical and immunologic reaction with amyloid or its precursor are under intensive development.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2003 Jul;443(1):3-16 [12802585.001]
  • [Cites] Am J Clin Pathol. 2001 Jul;116(1):135-42 [11447744.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):31466-73 [12070143.001]
  • [Cites] Mayo Clin Proc. 2002 Dec;77(12):1278-9 [12479511.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(7):591-6 [16062177.001]
  • [Cites] Nature. 2002 May 16;417(6886):254-9 [12015594.001]
  • [Cites] Tex Heart Inst J. 2005;32(2):178-84 [16107109.001]
  • [Cites] N Engl J Med. 1997 Apr 24;336(17):1202-7 [9110907.001]
  • [Cites] Clin Lymphoma. 2003 Mar;3(4):241-6 [12672274.001]
  • [Cites] N Engl J Med. 1997 Jan 23;336(4):267-76 [8995091.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2936-8 [15070667.001]
  • [Cites] Transplantation. 2005 Sep 27;80(1 Suppl):S160-3 [16286897.001]
  • [Cites] Kardiol Pol. 2005 Jul;63(7):20-35 [16136426.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):125-33 [15677530.001]
  • [Cites] Amyloid. 2002 Sep;9(3):197-200 [12408684.001]
  • [Cites] Lab Invest. 2004 May;84(5):545-52 [14968122.001]
  • [Cites] Curr Treat Options Cardiovasc Med. 2005 Dec;7(6):443-8 [16283971.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4276-82 [12036853.001]
  • [Cites] J Heart Lung Transplant. 2004 Oct;23 (10 ):1142-53 [15477107.001]
  • [Cites] J Med Chem. 2002 Jan 17;45(2):321-32 [11784137.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 May;125(5):1165-6 [12771895.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):886-9 [12060126.001]
  • [Cites] Circulation. 2005 Sep 27;112(13):2047-60 [16186440.001]
  • [Cites] Chest. 2001 Nov;120(5):1735-8 [11713162.001]
  • [Cites] Transplantation. 2003 Feb 27;75(4):560-1 [12605128.001]
  • [Cites] Heart. 2001 Feb;85(2):202-7 [11156673.001]
  • [Cites] Am J Hematol. 2003 Oct;74(2):131-5 [14508801.001]
  • [Cites] Circulation. 2002 Oct 15;106(16):2091-7 [12379579.001]
  • [Cites] J Immunol. 2002 Oct 1;169(7):4039-45 [12244207.001]
  • [Cites] Amyloid. 2001 Mar;8(1):52-7 [11293825.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1227-9 [16210334.001]
  • [Cites] J Intern Med. 2003 Sep;254(3):225-35 [12930231.001]
  • [Cites] Liver Transpl. 2003 Sep;9(9):986-92 [12942463.001]
  • [Cites] Amyloid. 2003 Jun;10(2):127-9 [12964421.001]
  • [Cites] Blood Rev. 2004 Mar;18(1):17-37 [14684147.001]
  • [Cites] Transplantation. 2001 Apr 15;71(7):986-92 [11349736.001]
  • [Cites] Curr Drug Targets. 2004 Feb;5(2):151-8 [15011948.001]
  • [Cites] Curr Opin Rheumatol. 2004 Jan;16(1):67-75 [14673392.001]
  • [Cites] Circulation. 2001 Dec 11;104(24):2996-3007 [11739319.001]
  • [Cites] Am J Med. 2002 Nov;113(7):549-55 [12459400.001]
  • [Cites] Kidney Int. 2002 Jan;61(1):1-9 [11786079.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:257-82 [15561687.001]
  • [Cites] Ann Intern Med. 2004 Jan 20;140(2):85-93 [14734330.001]
  • [Cites] Virchows Arch. 2006 Jul;449(1):88-95 [16612621.001]
  • [Cites] Bone Marrow Transplant. 2001 Aug;28(4):381-5 [11571511.001]
  • [Cites] N Engl J Med. 2005 Feb 17;352(7):722-3 [15716569.001]
  • [Cites] J Clin Pathol. 2003 Feb;56(2):86-90 [12560384.001]
  • [Cites] N Engl J Med. 2003 Aug 7;349(6):583-96 [12904524.001]
  • (PMID = 17078911.001).
  • [ISSN] 1092-8464
  • [Journal-full-title] Current treatment options in cardiovascular medicine
  • [ISO-abbreviation] Curr Treat Options Cardiovasc Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Mioulet D, Braem L, Heno P, Paule P, Peloni JM, Bonnet D, Fourcade L: [Cardiac extension of a non-Hodgkin lymphoma revealed by an atrial flutter]. Ann Cardiol Angeiol (Paris); 2009 Apr;58(2):117-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiac extension of a non-Hodgkin lymphoma revealed by an atrial flutter].
  • Primary or secondary cardiac lymphomas are not frequent.
  • Our case report, which is a slow atrial flutter with a pericardial effusion, is an uncommon discovery mode for a malignant lymphoma.
  • Their diagnosis and the mechanism of the arythmia were allowed by non-invasive cardiac imagery (transesophageal echography and magnetic resonance imaging), which showed a tumour-like infiltration of the right atrium, of the right ventricle posterior wall, and of the atrioventricular junction.
  • The diagnosis of a high grade B cell malignant non-hodgkin lymphoma, involving the bone marrow, the liver and the kidneys was made by biopsies of lymph nodes, histological analysis of the bone marrow, and a body CT scan.
  • Throughout the first chemotherapy sequence, we observed a spontaneous return to a sinusal rhythm, and the cardiac MRI showed a regression of the myocardial infiltration and of the pericardial effusion; moreover, the patient's state improved and the peripheral lymph nodes shrank back to a normal size.
  • However, the patient passed away, due to neurological complications 13 months after the diagnosis of lymphoma, without recurrence of cardiac involvement.
  • [MeSH-major] Atrial Flutter / etiology. Heart Neoplasms / complications. Lymphoma, B-Cell / complications

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657797.001).
  • [ISSN] 1768-3181
  • [Journal-full-title] Annales de cardiologie et d'angéiologie
  • [ISO-abbreviation] Ann Cardiol Angeiol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


31. Persoon S, Kersten MJ, Chinapaw MJ, Buffart LM, Burghout H, Schep G, Brug J, Nollet F: Design of the EXercise Intervention after Stem cell Transplantation (EXIST) study: a randomized controlled trial to evaluate the effectiveness and cost-effectiveness of an individualized high intensity physical exercise program on fitness and fatigue in patients with multiple myeloma or (non-) Hodgkin's lymphoma treated with high dose chemotherapy and autologous stem cell transplantation. BMC Cancer; 2010;10:671
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Design of the EXercise Intervention after Stem cell Transplantation (EXIST) study: a randomized controlled trial to evaluate the effectiveness and cost-effectiveness of an individualized high intensity physical exercise program on fitness and fatigue in patients with multiple myeloma or (non-) Hodgkin's lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.
  • BACKGROUND: The use of high-dose chemotherapy combined with autologous stem cell transplantation has improved the outcome of hematologic malignancies.
  • Nevertheless, this treatment can cause persistent fatigue and a reduced global quality of life, role and physical function.
  • The aims of the present study are (1) to determine the effectiveness of an individualized high intensity strength and interval training program with respect to physiological and psychological health status in patients with multiple myeloma or (non-)Hodgkin's lymphoma who have recently undergone high dose chemotherapy followed by autologous stem cell transplantation; and (2) to evaluate the cost-effectiveness of this program.
  • The primary outcomes (cardiorespiratory fitness, muscle strength and fatigue) and secondary outcomes are assessed at baseline, at completion of the intervention and at 12 months follow-up.
  • [MeSH-major] Cost-Benefit Analysis. Fatigue / prevention & control. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Multiple Myeloma / therapy. Physical Fitness. Research Design. Resistance Training / economics. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Blood Pressure. Chemotherapy, Adjuvant / adverse effects. Counseling / economics. Employment. Exercise Test. Forced Expiratory Volume. Health Care Costs. Heart Rate. Humans. Muscle Strength. Netherlands. Oxygen Consumption. Prospective Studies. Quality of Life. Recovery of Function. Single-Blind Method. Surveys and Questionnaires. Time Factors. Transplantation, Autologous. Treatment Outcome. Vital Capacity


32. Davidson MH: Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs; 2001;61(2):197-206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.
  • Hypercholesterolaemia is a chronic condition that often requires life-long treatment, making the safety of lipid-lowering drugs a critical issue.
  • 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors ('statins') are commonly used as the pharmacotherapeutic treatment of choice for patients with hypercholesterolaemia.
  • These agents have consistently demonstrated a positive safety and tolerability profile, and are recommended by the US National Cholesterol Education Program guidelines and by the European Joint Task Force for Prevention of Coronary Heart Disease to be used after, or in addition to, a first-line approach with diet.
  • Several large-scale clinical trials have shown HMG-CoA reductase inhibitors to be efficacious and well tolerated, and to be associated with a low rate of treatment withdrawal due to adverse events.
  • These studies included mortality and morbidity end-points, and comprised both primary- and secondary-prevention trials.
  • Hepatic, renal and muscular systems are rarely affected during HMG-CoA reductase inhibitor therapy and the few drug interactions that can occur with concomitantly administered drugs are well documented.
  • Thus, it can be concluded that HMG-CoA reductase inhibitors are well tolerated, effective treatments for hypercholesterolaemia.
  • [MeSH-major] Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects. Hypercholesterolemia / drug therapy
  • [MeSH-minor] Anticholesteremic Agents / adverse effects. Anticholesteremic Agents / pharmacology. Anticholesteremic Agents / therapeutic use. Clinical Trials as Topic. Coronary Disease / drug therapy. Humans. Naphthalenes / adverse effects. Naphthalenes / therapeutic use. Stroke / etiology. Violence

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • MedlinePlus Health Information. consumer health - Statins.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 Nov 16;333(20):1301-7 [7566020.001]
  • [Cites] Am J Health Syst Pharm. 1995 Aug 1;52(15):1639-45 [7583826.001]
  • [Cites] JAMA. 1993 Jun 16;269(23):3015-23 [8501844.001]
  • [Cites] Am J Clin Nutr. 2000 Jan;71(1 Suppl):331S-8S [10617992.001]
  • [Cites] JAMA. 1998 May 27;279(20):1615-22 [9613910.001]
  • [Cites] Ann N Y Acad Sci. 1997 Dec 29;836:57-80 [9616794.001]
  • [Cites] N Engl J Med. 1996 Oct 3;335(14):1001-9 [8801446.001]
  • [Cites] Arch Intern Med. 1998 Mar 23;158(6):577-84 [9521221.001]
  • [Cites] Am J Cardiol. 1998 Mar 1;81(5):582-7 [9514454.001]
  • [Cites] Ann Intern Med. 1988 Oct 15;109(8):682-3 [3421582.001]
  • [Cites] N Engl J Med. 1988 Jan 7;318(1):46-7 [3275891.001]
  • [Cites] Ann Pharmacother. 1998 Oct;32(10):1030-43 [9793596.001]
  • [Cites] Am J Cardiol. 1994 Oct 1;74(7):667-73 [7942524.001]
  • [Cites] Arch Intern Med. 1994 Jun 27;154(12):1317-21 [8002683.001]
  • [Cites] Arch Intern Med. 1991 Jan;151(1):43-9 [1985608.001]
  • [Cites] Stroke. 1996 Nov;27(11):1993-8 [8898804.001]
  • [Cites] Ann Intern Med. 1988 Oct 1;109(7):597-8 [3421570.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1349-57 [9841303.001]
  • [Cites] Clin Pharmacol Ther. 1998 Nov;64(5):477-83 [9834039.001]
  • [Cites] Am J Cardiol. 1997 Aug 1;80(3):278-86 [9264419.001]
  • [Cites] N Engl J Med. 1999 Aug 5;341(6):410-8 [10438259.001]
  • [Cites] Drugs. 1998 Mar;55(3):415-20; discussion 421-2 [9530546.001]
  • [Cites] Pharmacol Res. 1990 Sep-Oct;22(5):555-63 [2126139.001]
  • [Cites] Jpn Circ J. 1999 Jan;63(1):53-8 [10084389.001]
  • [Cites] Arch Intern Med. 1993 May 10;153(9):1079-87 [8481075.001]
  • [Cites] Arch Intern Med. 1990 Oct;150(10):2169-72 [2222103.001]
  • [Cites] J Neurooncol. 1999 Mar;42(1):1-11 [10360474.001]
  • [Cites] Hypertension. 1999 Oct;34(4 Pt 2):987-96 [10523396.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1995 May;15(5):678-82 [7749881.001]
  • [Cites] Biochim Biophys Acta. 1992 Jan 24;1123(2):133-44 [1739744.001]
  • [Cites] JAMA. 1990 Jul 4;264(1):71-5 [2355431.001]
  • [Cites] N Engl J Med. 1989 Apr 6;320(14):904-10 [2619783.001]
  • [Cites] N Engl J Med. 1987 Nov 12;317(20):1237-45 [3313041.001]
  • [Cites] Am Fam Physician. 1998 May 1;57(9):2192-2204, 2207-8 [9606309.001]
  • [Cites] Am J Cardiol. 1997 Jun 1;79(11):1475-81 [9185636.001]
  • [Cites] Health Rep. 1994;6(1):28-38 [7919086.001]
  • [Cites] N Engl J Med. 1995 Sep 7;333(10):664-5 [7637734.001]
  • [Cites] Atherosclerosis. 1997 Apr;130(1-2):191-7 [9126664.001]
  • [Cites] N Engl J Med. 1999 Jul 8;341(2):70-6 [10395630.001]
  • [Cites] Lancet. 1994 Nov 19;344(8934):1383-9 [7968073.001]
  • [Cites] Leuk Lymphoma. 1997 Feb;24(5-6):533-7 [9086443.001]
  • [Cites] JAMA. 1984 Jan 20;251(3):351-64 [6361299.001]
  • [Cites] Blood. 1999 Feb 15;93(4):1308-18 [9949174.001]
  • [Cites] Atherosclerosis. 1998 Oct;140(2):199-270 [9862269.001]
  • [Cites] Am J Cardiol. 1994 May 26;73(14):25D-29D [8198020.001]
  • [Cites] JAMA. 1996 Jan 3;275(1):55-60 [8531288.001]
  • (PMID = 11270938.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Naphthalenes
  • [Number-of-references] 49
  •  go-up   go-down


33. Khan NU, Ahmed S, Wagner P, Rumley RL, Movahed A: Cardiac involvement in non-Hodgkin's lymphoma: with and without HIV infection. Int J Cardiovasc Imaging; 2004 Dec;20(6):477-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac involvement in non-Hodgkin's lymphoma: with and without HIV infection.
  • AIDS has resulted in a significant increase in the incidence of both primary and secondary cardiac lymphomas.
  • Prognosis of HIV associate cardiac non-Hodgkin's lymphoma is poor with very limited survival.
  • Many cases of cardiac involvement in lymphoma remain undetected secondary to non-specific symptoms.
  • Chemotherapy may produce remission in some cases.
  • We report two cases of cardiac involvement with B-cell lymphoma.
  • [MeSH-major] HIV Infections / pathology. Heart Neoplasms / pathology. Lymphoma, AIDS-Related / pathology. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Adult. Aged. Female. HIV Seronegativity. Humans. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Neoplasm Staging. Prognosis


34. Podol'skiĭ PN, Datsenko PV, Pan'shin GA, Sotnikov VM, Mel'nik IuD, Ivashin AV, Bozhenko VK: [Multivariate analysis of risk of cardiac complications in Hodgkin's lymphoma]. Vopr Onkol; 2009;55(4):447-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivariate analysis of risk of cardiac complications in Hodgkin's lymphoma].
  • A computer database was created to take care of a wide range of protocols for combined treatment of Hodgkin's disease stage I-IV (n=1,573).
  • Early-onset radiation-related injuries (pneumonitis) and exposure of lung tissues to radiation were identified as the main risk factors for cardiopathology development.
  • It is suggested that total focal dosage used after chemotherapy be reviewed since total dosage for the entire lymph collector in excess of 30 Gy might contribute to hazards of cardiopathology.
  • However, a locally administered TTD ranging 36-44 Gy to deal with residual tumor offers best advantage in preventing local relapse.
  • Our approach might promote individualization of prognosis as far as cardiac complications involved in Hodgkin's lymphoma are concerned.
  • [MeSH-major] Heart / radiation effects. Heart Diseases / etiology. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Heart Neoplasms / secondary. Humans. Male. Mechlorethamine / administration & dosage. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pneumonia / etiology. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Assessment. Risk Factors. Survival Analysis. Vincristine / administration & dosage


35. Diehl V, Fuchs M, GHSG: Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages? Transfus Apher Sci; 2007 Aug;37(1):37-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
  • Hodgkin Lymphoma (HL) has become one of the most curable cancers, even in adulthood, through continuous improvement of therapeutic options and their verification by large multicenter trials.
  • Nevertheless, these good results are threatened by treatment associated toxicities such as infertility, cardiopulmonary toxicity and secondary malignancies.
  • It is therefore the aim of future trial generations both to maintain the excellent treatment results and to minimize late effects.
  • In 1964 for the first time deVita et al. described the MOPP polychempotherapy for patients with advanced HL which led to cure rates in more than 50%.
  • Around ten years later Bonadonna et al. established the non cross resistant alternative regime to MOPP, ABVD which nowadays is accepted as "gold standard" for the treatment of advanced HL.
  • Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
  • N Engl J Med 2003; 348: 2386-95] to improve the efficacy of COPP/ABVD by time- and dose-intensification, omission of Velban and Dacarbazin and adding Etoposide resulting in the BEACOPP principle.
  • From the initial pilot studies in 1992 three trial generations, HD9, HD12, HD15, have now established this principle as one of the most effective chemotherapy regimen in advanced HL.
  • We certainly hope that it will not last another 20 years to establish the BEACOPP regimen as an attractive curative treatment option for at least the high risk cohorts of HL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Bleomycin / adverse effects. Bleomycin / standards. Bleomycin / therapeutic use. Clinical Trials as Topic. Cyclophosphamide / adverse effects. Cyclophosphamide / standards. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Disease-Free Survival. Doxorubicin / adverse effects. Doxorubicin / standards. Doxorubicin / therapeutic use. Etoposide / adverse effects. Etoposide / standards. Etoposide / therapeutic use. Heart Diseases / chemically induced. Humans. Infertility / chemically induced. Lung Diseases / chemically induced. Mechlorethamine / therapeutic use. Multicenter Studies as Topic. Neoplasm Staging. Neoplasms, Second Primary / chemically induced. Prednisone / adverse effects. Prednisone / standards. Prednisone / therapeutic use. Procarbazine / adverse effects. Procarbazine / standards. Procarbazine / therapeutic use. Risk. Survival Rate. Vinblastine / therapeutic use. Vincristine / adverse effects. Vincristine / standards. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17714996.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; MOPP protocol
  • [Number-of-references] 14
  •  go-up   go-down






Advertisement